Home > Publications Database > Secreted APP Modulates Synaptic Activity: A Novel Target for Therapeutic Intervention? > print

001     140495
005     20240321220823.0
024 7 _ |a 10.1016/j.neuron.2019.01.058
|2 doi
024 7 _ |a pmid:30790537
|2 pmid
024 7 _ |a 0896-6273
|2 ISSN
024 7 _ |a 1097-4199
|2 ISSN
024 7 _ |a altmetric:55809025
|2 altmetric
037 _ _ |a DZNE-2020-06817
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Haass, Christian
|0 P:(DE-2719)2202037
|b 0
|e First author
|u dzne
245 _ _ |a Secreted APP Modulates Synaptic Activity: A Novel Target for Therapeutic Intervention?
260 _ _ |a New York, NY
|c 2019
|b Elsevier
264 _ 1 |3 print
|2 Crossref
|b Elsevier BV
|c 2019-02-01
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1592562515_22058
|2 PUB:(DE-HGF)
|x Editorial
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The amyloid precursor protein (APP) is not only processed to the neurotoxic amyloid-β peptide but also to various types of secreted APP variants. In a recent issue of Science, Rice et al. (2019) now demonstrate that secreted APP functions as a modulator of synaptic transmission by binding to GABABR1a.
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
542 _ _ |i 2019-02-01
|2 Crossref
|u https://www.elsevier.com/tdm/userlicense/1.0/
542 _ _ |i 2020-02-20
|2 Crossref
|u http://www.elsevier.com/open-access/userlicense/1.0/
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 2 |a Amyloid beta-Peptides
|2 MeSH
650 _ 2 |a Amyloid beta-Protein Precursor
|2 MeSH
650 _ 2 |a Biological Transport
|2 MeSH
650 _ 2 |a Ligands
|2 MeSH
650 _ 2 |a Synaptic Transmission
|2 MeSH
700 1 _ |a Willem, Michael
|0 P:(DE-2719)9000433
|b 1
|e Last author
|u dzne
773 1 8 |a 10.1016/j.neuron.2019.01.058
|b : Elsevier BV, 2019-02-01
|n 4
|p 557-559
|3 journal-article
|2 Crossref
|t Neuron
|v 101
|y 2019
|x 0896-6273
773 _ _ |a 10.1016/j.neuron.2019.01.058
|g Vol. 101, no. 4, p. 557 - 559
|0 PERI:(DE-600)2001944-0
|n 4
|q 101:4<557 - 559
|p 557-559
|t Neuron
|v 101
|y 2019
|x 0896-6273
909 C O |o oai:pub.dzne.de:140495
|p VDB
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2202037
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 1
|6 P:(DE-2719)9000433
913 1 _ |a DE-HGF
|b Forschungsbereich Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|2 G:(DE-HGF)POF3-300
|v Disease Mechanisms and Model Systems
|x 0
914 1 _ |y 2019
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2022-11-16
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-16
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NEURON : 2021
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-16
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-16
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-16
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NEURON : 2021
|d 2022-11-16
920 1 _ |0 I:(DE-2719)1110007
|k AG Haass old
|l ALS, FTLD and Zebrafish models
|x 0
920 1 _ |0 I:(DE-2719)5000048
|k Ext LMU
|l Ext Ludwig-Maximilians-University
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)5000015
980 _ _ |a I:(DE-2719)5000048
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21